AirXpanders, Inc., the developers of the AeroForm Tissue Expander System, announced that the AeroForm technology was featured at the Barcelona Breast Meeting (BBM), which took place March 16-17, in Barcelona, Spain.
The BBM brings together plastic surgeons and microsurgeons from Europe to educate them on products and research developments in breast reconstructive and breast aesthetic surgery. During BBM, Kamakshi Zeidler, M.D., FACS, a board-certified plastic surgeon and Managing Partner at Aesthetx in Campbell, California, reviewed the results from the XPAND randomized clinical trial and shared her personal experience treating patients with the AeroForm System. Dr. Zeidler served as a clinical investigator for AirXpanders’ U.S. XPAND and XPAND II clinical trials and recently performed the first commercial AeroForm procedure in the U.S. following FDA’s de novo marketing authorization.
Additionally, AeroForm was featured during the Gadget Show, which focuses specifically on breast reconstruction technology. AirXpanders’ President and CEO, Scott Dodson, provided an overview of the technology.
“With the commercial launch of AeroForm now underway in the United States, our next goal is to connect with a global network of reconstructive experts,” says Dodson. “The interest and excitement in AeroForm during BBM was palpable, and we look forward to working with these experts to identify a path to make our technology available in Europe in the future.”
AeroForm offers a needle-free alternative for women who choose reconstructive surgery following a mastectomy. AeroForm is activated by a handheld wireless controller that administers small amounts of carbon dioxide (CO2) up to three times a day, to gradually stretch the tissue to prepare for a breast implant. With the push of a button from the wireless controller, a preprogrammed amount of CO2 is delivered in seconds, allowing the patient to continue with her daily activities while preparing for reconstruction.